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GASTRIC REMNANT CARCINOMA: 
mSTOCHEMICAL AND IMMUNOHISTOCHEMICAL PROFILE 
ABSTRACT 
Gastric remnant carcinoma (GRC) is a gastric cancer that develops in gastric remnant more 
than five years after resection for benign disease. GRC comprises 1 %-9% of all gastric 
cancers. Partial gastrectomy for peptic ulcer is thought to be a risk factor for GRC. 
Pancreato-duodenal and bile reflux may play an important part in the aetiology of GRC. 
Primary gastric carcinoma (pGC) is a gastric cancer that arises in un-operated stomach and 
chronic gastritis is a well-known risk factor. Consequently there appear to be differences in 
the aetiology of GRC and PGC. According to many studies, surgical treatment of early GRC 
(Stage I or II) resulted in the same or better prognosis with similar stage PGC. However if 
diagnosed late, GRC has a worse prognosis than PGC at the same stage. In this study 
haematoxylin and eosin, alcian blue pH 2.5, periodic acid Schiff, high iron diamine and 
Giemsa stains as well as immunohistochemical methods (eight antibodies against MUCI to 
MUC6) were used to detennine the type of mucin and the pattern of staining in twenty cases 
of GRC and twenty PGC (ten cases of intestinal type PGC, ten diffuse type PGC) and ten 
nonnal gastric mucosal biopsies. The aim of the study was to describe the morphology of 
GRC and the adjacent gastric mucosa, as well as to determine the histochemical and 
immunohistochemical mucin profile of GRC and to compare this with that of PGC and 
nonnal mucosa. 
In general, morphologically, histochemically and imunohistochemically, gastric remnant 
carcinoma closely resembles primary gastric carcinoma. This includes the findings of a high 
association of Type I and lIB intestinal metaplasia in the intestinal types of both GRC and 
PGC compared to the diffuse types of GRC and PGC, although a smaller percentage of GRCs 
expressed MUCI and MUC2 than PGCs. 
ix 
CHAPTER ONE 
INTRODUCTION 
1.1 NORMAL STOMACH 
The stomach is a dilated portion of the alimentary canal, located in the left 
hypochondrium and epigastric region of the abdomen. It has the cardia and the 
pyloric orifices. It has the greater and lesser curvatures and two surfaces, an anterior 
and posterior surface respectively. 
The stomach is an organ of storage and digestion. Embryologically, the stomach 
arises from the foregut. The blood supply is mainly by the coeliac artery. It can 
accommodate more than two litres of fluid (Snell 1992). 
The stomach is anatomically divided into four regions. 
1) The gastric cardia: is the part of the stomach located adjacent to the gastro-
oesophageal junction. 
2) The fundus: is dome-shaped and located above the level of the gastro-
oesophageal junction. 
3) The corpus or body: constitutes the major portion of the stomach. 
4) The pylorus: located distally and subdivided into pyloric antrum, pyloric canal 
and pyloric sphincter. 
The wall of the stomach is divided into mucosa, submucosa, muscularis propria and 
adventitia. The mucosa of the stomach is thick and thrown into numerous folds or 
rugae. The mucosa consists of an epithelial layer, lamina propria and muscularis 
mucosa. The gastric glands in the body and fundus are relatively straight and not 
coiled. The mucus secreting cells are limited to the upper portions of the glands. The 
mucus surface cells produces mucus that is chemically distinct from that produced by 
the mucus neck cells. Gastric glands of both fundus and body contain parietal cells 
that secrete hydrochloric acid. The body of the stomach is the main special secretory 
area and it contains parietal and chief cells. The parietal cells are responsible for the 
secretion of intrinsic factor, which facilitate the absorption of vitamin B t2 • Chief cells 
secrete large amounts of zymogen. Mucosal glands of the cardia and pylorus are 
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mostly devoid of acid secretory cells. Gastric pits in the cardiac and pyloric regions 
lead to glands that are coiled, lined mostly by mucus cells. Gastric mucosa also 
contains cells that are part of the enterochromaffin system. G cells are found in the 
region of the antrum and secrete gastrin, which promotes parietal cell secretion of 
hydrochloric acid. Gastrin also stimulates antral motor activity. Gastrin activity is 
inhibited by acidity. Cells termed I cells, found in much of the stomach secrete 
cholecystokinin which stimulates the release of pancreatic secretions rich in protein. 
S cells are found in the distal stomach and secrete secretin that stimulates alkaline 
secretions from the pancreas (Snell 1992, WastellI991). 
Gastric surgery has many complications, (Cuschieri 1995) which include: (palmer 
1991): 
I} Small stomach syndrome associated with a feeling of fullness after only a 
moderately sized meal. 
2} Bilious vomiting. 
3} Anemia due to iron deficiency anemia or occasionally vitamin B12 deficiency due 
to loss of intrinsic factor. 
4} The dumping syndrome comprises attacks of fainting and sweating after food 
intake. This is probably an osmotic effect due to the high osmolarity of the 
gastric content, which passes rapidly into the jejunum, absorbing fluid into the 
gut lumen and producing a temporary reduction in the circulating blood volume. 
5} Steatorrhoea, the production of fatty stool. 
. 6} Stomal ulceration, which is more common after duodenal ulceration and very rare 
after gastric ulcer surgery. 
1} Gastric remnant carcinoma. 
1.2 MUCINS 
1.2.1 MUCIN SECRETION, STRUCTURE, DISTRIBUTION AND FUNCTION 
Mucus is a slimy, sticky secretion that coats epithelial surfaces in 99"10 of 
invertebrates (Denny 1989, Devine et al. 1992, Kim et al. 1995, Gevers 1981). 
Mucins are glycoproteins of large molecular weight that are the main components of 
mucus and impart gel~forming properties to it (Allen 1981, Mall et al. 1990). Mucins 
consist of a non-globular thread~like protein core, which contains a high level of 
serine, theonine, alanine, glycine and proline (Devine et al. 1992, De Kretser et al. 
1986, Seregni et at. 1991) and contains both highly glycosylated and naked regions. 
(Allen 1981). The cores of different mucins vary in size, amino acid sequence and 
2 
the number of tandem repeats. Each tandem repeat is specific to a specific mucin 
type (Jass 2000). 
The primary function of mucus is to form a protective cover over epithelial surfaces 
in the stomach, colon, gall bladder and tracheobronchial tree (Allen 1981). In the 
stomach the mucous barrier is a continuous layer of water insoluble gel, of median 
thickness 180 um in humans, which adheres to the epithelium and protects it from the 
high shear forces associated with digestion (Allen 1981). In gastric ulcer patients, the 
gel is substantially weaker, containing less polymeric mucin (Allen 1990, Younan et 
al 1982). Alteration of mucins such as altered glycosylation patterns have been 
reported to occur in gastric and colonic adenocarcinoma (Feizi 1985). 
1.2.2 mSTOCIlEMISTRY OF GASTRIC MUCIN 
Gastric mucins have been classified as neutral or acidic mucins, the latter of which is 
also subdivided into sulphomucin and sialomucins according to the reaction with 
periodic acid Schiff (PAS), alcian blue and high iron diamine (Segura et al. 1983). 
Normal gastric epithelium shows predominantly neutral mucins that stain positively 
for PAS. Sulphomucin and sialomucin are not expressed in a significant amount in 
the normal stomach. Sialomucin can be weakly expressed in the base of the fundus 
pits, while sulphomucin is faintly expressed in the mucus cells of the normal stomach. 
Cardiac glands at the gastro-esophageal junction can secrete small amount of 
sulphomucins and sialomucin as well as the normal neutral mucin (Jass 1996). 
Intestinal metaplasia shows positive staining for the acidic mucins with or without the 
expression of neutral mucins. Intestinal adenocarcinoma expresses neutral, acidic 
and some sUlphomucin (Taylor et al. 1998). 
1.2.3 MUCIN GENES 
Human mucins are derived from a heterogeneous family of genes. There are at least 
15 different mucins genes that have now been identified and described (MUC1, 2, 
3A, 3B, 4, SAC, 5B, 6, 7, 8, 9,10,11,12 andMUCI3). 
MUCI is a membrane-associated mucin (Kim et al. 1995) that consists of an 
extracellular and a membrane-associated domain (Silverman et al. 2001). The gene is 
located on chromosome 1q21-24 and it is fully sequenced (Swallow et al. 1987a, 
1987b). MUC1 glycoprotein is primarily a mammary-type apomucin, that is also 
expressed in bronchial epithelium, salivary gland, pancreas, and prostatic and uterine 
epithelium. In the gastrointestinal tract, MUC1 is strongly expressed in the base of 
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colonic crypts, in colonic goblet cells and colunmar cells (Tashiro et aL 1994). In the 
stomach MUCI is expressed in the apical and cytoplasmic region of foveolar 
epithelium and mucus neck cells. Parietal cells also show diffuse cytoplasmic 
staining of MUC1 (Winterford et al. 1999). Ultrastructural studies showed that 
MUC1 is located in the secretory vesicles and along the microvillous brush border of 
colunmar cells and the cytoplasmic remnants of the goblet cells (Winterford et at. 
1999). MUCI core peptide is highly expressed on apical membranes of the bronchus, 
breast, salivary gland, pancreas, prostate, and uterus and is sparsely expressed in the 
gastric surface cells, gallbladder, small intestine, and colonic epithelium. Increased 
expression of MUC1 was observed in adenocarcinoma of the breast and ovary 
(Tashiro et al. 1994), with the expression ofMUCI in breast carcinoma found to be 
associated with better differentiation and a better prognosis (Rahn et at. 2001). 
MUC2 is a secretory gel-forming mucin (Kim et at. 1995). The gene is located on 
chromosome IlpI5.5. It is present in a cluster that also includes MUC5AC, MUC5B 
and MUC6. MUC2 is the predominant form of mucin in human intestinal and colonic 
tissue and is considered to be specific to goblet cells (Gum et al. 1992). MUC2 is 
weakly expressed in the tracheobronchial tree (Gum et al. 1992). 
MUC3 is a membrane bound mucin, encoded on chromosome 7q22 and expressed in 
the small intestine and colorectum, salivary gland and gall bladder (Shekels et at. 
1998). MUC3 antibody stains both goblet and colonic epithelial cells, but is not 
expressed in the normal gastric mucosa (Ho et al. 1993). More recent evidence 
suggests that MUC3 consists of two genes, MUC3A and MUC3B, both of which 
encode membrane-bound mucins (Kyo et a12001) 
The MUC4 gene is localized to chromosome 3q29 (porchet et al 1995). It is a trans-
membrane protein with two extra cellular epidermal growth factor like domains that 
may bind to c-erb-2 (Moniaux et al. 1999). It is expressed in the respiratory and 
reproductive tracts and gastric mucosa, and to a lesser extent by goblet cells of the 
colorectum (Winterford et al. 1999, Seregni et al. 1997). Colorectal cancer shows 
loss of expression of MUC4 (Biemer-Huttman et al. 2000). 
MUC5AC is a secretory gel-forming mucin, normally expressed in the superficial 
and foveolar epithelium of gastric mucosa and neck cells and absent in the deep 
glands of the gastric body and pyloric glands of the antrum (Machado et al. 2000). 
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MUC5B is highly expressed in the respiratory epithelium (Seregni et al. 1997). 
MUC6 is a major mucin in the stomach (Kim et at. 1995). It is predominantly 
expressed in the neck mucus cells of gastric antrum, pyloric glands, and principle 
cells of the gastric body (Machado et al. 2000). It is also expressed in the gall 
bladder, pancreatic ductules and seminal vesicle. 
MUC7 gene is located in chromosome 4q13-q21, which has been fully sequenced and 
has previously been called MG2. It is approximatelylO.O kb in length. It encodes a 
low molecular weight mucin (Bobek et al. 1993) and is expressed in the salivary 
glands (Bobek et at. 1996). 
MUC8 has recently been cloned. It is localized to chromosome 12q24.3 and is 
normally expressed by the submucosal glands of the human trachea (Shankar et at. 
1997). 
MUC9 is also known as ovicductin, and has been identified in the rabbit endocervix 
(Hendrix et al. 2001). The gene for MUC9 is localized to chromosome 1 p 13 and its 
likely functions include protection of the early embryo and the fallopian tube 
(Lapensee et al. 1997). 
MUCIO has been described in the submandibular salivary glands of embryonic 
mouse and it is possibly involved in the gland development (Melnick et al. 2001). 
MUCH and MUC12 were described by Williams et at. (1999). They are down 
regulated in colorectal cancer and both are mapped to chromosome band 7q22 
(Williams et al. 1999). MUCII is a 2.8 kb long. MUC12 encodes a trans-membrane 
mucin and it is a homologous with epidermal growth factor-like growth factors, 
suggesting that MUC12 may be involved in epithelial cell growth regulation 
(Williams et aL 1999). 
MUC13 is localized to chromosome band 3q13.3. It encodes a 512 amino acid 
protein. It is a novel human cell surface transmembrane mucin, which is expressed 
by epithelial and hemopoietic cells. MUC13 is highly expressed in the large intestine 
and trachea. MUC13 is expressed at a mild level in small intestine, kidney, appendix 
and stomach. Immunohistochemical staining has shown that MUC13 is expressed on 
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the apical membrane of gastrointestinal columnar cells and cytoplasm of goblet cells 
(Williams et al. 2001). 
1.2.4 MUCIN EXPRESSION IN NORMAL AND DISEASED STOMACH 
1.2.4.1 Normal Stomach 
There are some conflicting and controversial results arising from studies of mucin 
expression in the normal stomach. Buisine et al. (2000) demonstrated that MUCI and 
MUC5AC are strongly expressed in normal stomach with weak or negative MUC6, 
MUC2, MUC3 and MUC4 staining and negative for MUC5B and MUC7. Taylor et 
al. (1998) showed strong expression of MUC4, MUC5 and MUC6 and weak or no 
expression of MUCI in the normal stomach. Ho et al. (1995) showed strong 
expression of MUC5 and MUC6, but weak faint positivity of MUCI and absence of 
MUC2, MUC3 and MUC4 staining in the normal stomach. 
1.2.4.2 Intestinal Metaplasia 
Histochemically, intestinal metaplasia is classified into the complete type (type 1), 
incomplete type (type llA) and incomplete (type lIB) that is positive for 
sulphomucins. Complete intestinal metaplasia is negative for MUC5AC and positive 
for MUC2. In incomplete intestinal metaplasia there is a combined positivity of 
MUC5AC and MUC2 (Jass et al. 2000). Intestinal metaplasia shows strong 
expression of MUC2 in the supra-nuclear area of goblet cells and strong MUC3 
reactivity in columnar cells with no expression of MUC4, MUC5 and MUC6 (Buisine 
et al. 2000, Ho et al. 1995). 
1.2.4.3 Effect of H.pylori on Mucins Expression in the Stomach 
Three human mucin genes are expressed strongly in the normal stomach: MUCI a 
membrane-bound mucin, MUC5AC and MUC6, which are expressed in surface 
mucous cells and mucous glands respectively (Byrd et al. 1997, de Bolos et al. 1995, 
Ho et al. 1995). H.pylori can bind to gastric mucins and results in either inhibition, or 
potentiation of bacterial adhesion to the gastric epithelium (Murata et al. 1992). 
H.pylon infection alters the expression of gastric mucin on the surface epithelial 
cells. In H.pylon infected patients, MUC6 mucin is focally expressed in the surface 
mucous cells as well as mucous glands whilst MUC5 is expressed weakly on the 
surface. There is no alteration in the expression of the membrane bound MUCI 
(Byrd et al. 1997). Eradication of H.pylon results in the reversal of surface 
MUC5AC and MUC6 expression to normal patterns (Byrd et al. 1997). 
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Molecular mimicry between Hpy/ori lipopolysaccharide structures and host mucin-
associated antigens could lead to protection from host immune surveillance and 
promote colonization (Appelmelk et al. 1996, Byrd et aI. 1997). 
1.2.4.4 Gastric carcinoma 
Acidic mucins are found in the majority of gastric cancers, but intestinal and diffuse 
cancers differed in the proportions of acid and neutral mucins secreted (Jass 1996). 
Jass (1996) reported that acidic mucin and particularly sulphomucin predominated 
in intestinal cancer, whereas neutral mucins were more abundant in cancers of the 
diffuse type. There are striking differences in both quality and quantity of mucin 
gene expression in PGC compared with normal gastric mucosa. Gastric cancer is 
usually associated with a decrease in mucin of the normal gastric type and the 
additional expression of mucin genes, which are normally expressed in the intestine 
(Ho et al. 1995). Early cancer and poorly differentiated carcinoma are associated 
with decrease and loss of mucin, but the advanced stage of well-differentiated 
adenocarcinoma is associated with multiple mucin gene expression (Torrado et al. 
1992). PGC shows altered mucin expression with loss ofMUC5AC and MUC6 in 
some tumor glands. It also shows abnormal expression of MUC2 and MUC3 with 
the appearance of MUC5B mRNA. MUCI expression has been observed to be 
expressed diffusely in the cytoplasm of the malignant cells, in addition to the 
expected normal apical membrane reactivity (Ho et al. 1995). MUC3 is increased in 
gastric adenocarcinoma. Marked differences in the mucin gene expression were 
noted between the different histological types of gastric cancer. Intestinal type 
carcinoma is more likely to express aberrant mucins compared with the diffuse type 
gastric carcinoma. PGC and fetal gastric epithelium may show similar mucin 
expression (Buisine et at. 2000, Ho et at. 1995). 
1.2.5 MUCIN EXPRESSION IN THE INTESTINE 
1.2.5.1 Normal Intestine and Tumours 
Since gastric carcinomas may be of intestinal type and can express intestinal type 
mucins that resemble mucins expressed in small bowel, it is important to know the 
types of mucin normally expressed in the normal bowel. Normal small bowel 
mucosa mainly shows the expression of MUC2 and MUC3 with less expression of 
MUCI and MUC4, and no expression ofMUC5AC, MUC5B, or MUC7. MUC6 is 
expressed mainly in the duodenum. MUC2 is expressed in the goblet cells and 
MUC3 by goblet and columnar cells of the bowel (Buisine et al 2001). Colonic 
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adenoma and carcinoma show an increase in the expression of MUCI and a 
decrease of the expression of MUC2 with increasing grades of epithelial dysplasia 
in adenomas (Jass 2000). MUC2 and MUC5AC are markedly increased in 
hyperplastic polyps and serrated adenoma (Jass et al. 2000). Colonic carcinomas 
show distinct patterns of MUC2 and MUC3 expression, although the expression of 
each were reduced compared with the levels in normal colonic mucosa (Chung et al. 
1994). 
1.2.6 SIGNIFICANCE OF THE STUDY OF MUCIN GENES 
Advanced stage carcinoma and poorly differentiated tumors are associated with the 
expression of aberrant multiple mucin core peptides (Bresalier et al. 1990). Increase 
mucin gene expression may contribute to tumor cell growth and metastatic change. 
Highly mucinous tumors are associated with worse prognosis in carcinomas of the 
colon (Nakamori et al. 1994). Mucin genes may provide a good target in cancer 
treatment (Hoff et al. 1989, Kuan et al. 1987). 
1.3 GASTRITIS 
1.3.1 Introduction 
Gastritis is the inflammation of the gastric mucosa and can be acute, chronic or a 
mixed gastritis. The mixed form is a combination of an acute and chronic 
inflammation, referred to as active chronic gastritis. Acute gastritis is diagnosed 
when there is neutrophil infiltration of the mucosa and glands, whilst in chronic 
gastritis, there is a chronic inflammatory cell infiltrate in the mucosa, of plasma cells 
and lymphocytes. Inflammation is a complex reaction involving an inflammatory cell 
infiltrate with alteration of the epithelial cells and the release of various mediators 
(Geboes 1992). The most common causes of acute gastritis are the heavy ingestion of 
non-steroidal anti-inflammatory drugs (NSAIDs), heavy smoking, excessive 
consumption of alcohol and or drugs, chemotherapy, radiotherapy, infection, shock, 
stress and uraemia. Acute gastritis can also be the result of the reflux of duodenal 
content. The most common known causes of chronic gastritis are H.py/ori, 
autoimmune gastritis, chemicals, tuberculosis and Crohn 's disease. Gastritis can be 
classified according to etiological, morphological or topographical information 
(Dixon et al. 1996). 
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1.3.2 CLASSIFICATION OF GASTRITIS 
1.3.2.1 Aetiological Classification: 
1.3.2.1.1 Upylori Associated Gastritis: H pylori is a slender gram-negative bacillus. 
However they are occasionally present in the stomach in coccoid forms (Chan et al. 
1994). H. pylori can be identified by histological and serological methods or by 
breath tests. H. pylori infection is very common throughout the world, but most 
infected individuals remain asymptomatic for years or even for decades (Blaser 
1992). H. pylori is the major cause of gastritis, especially chronic diffuse superficial 
gastritis (Graham 1989). H. pylori has also been linked to gastric ulcer, gastric 
carcinoma and gastric lymphoma (Veenedaal et al. 1996). H. pylori has been 
identified as a gastric carcinogen (Correa 1995, Hansson et al. 1995) but the exact 
mechanism of carcinogenesis is not known. H. pylori infection induces apoptosis in 
gastric epithelium by producing many cytotoxins (VacA), lipopolysaccharides and 
nitric oxide. H.pylori induces the release of host inflammatory and immune 
responses, which lead to the release of cytokines that potentiate apoptosis. 
Increased apoptosis is seen in all pre-cancerous conditions of the stomach and is 
associated with the development of gastric carcinoma, including intestinal and 
diffuse types (Xia et al. 2001). Chronic superficial gastritis may ultimately progress 
to involve gastric epithelium and glands, leading to chronic atrophic gastritis and to 
gastric atrophy (Morris et al.1987). H. pylori induced acute gastritis cause transient 
hypochlorhydria (Morris et a1.1987, Sobala et a1.1991). The exact mechanism 
remains unclear, but one hypothesis claims that the function of the parietal cell is 
directly affected (Cave et a1.1989). However most studies show that basal acid 
secretion does not seem to differ markedly between infected and uninfected controls 
(Morris et al. 1998). When no H. pylori can be identified and changes are short of 
other diagnostic categories, the gastric biopsy is reported as chronic gastritis without 
further qualification. Crohn' s disease should be suspected in a case of H. pylori 
negative focal gastritis according to Correa et al. (1992). 
1.3.2.1.2 Chemical Induced Gastritis 
This disease is also known as reactive gastropathy and reflux gastritis. The causes 
of chemical gastritis include alcohol, non-steroidal anti-inflammatory drugs 
(NSAID) and bile reflux (Dixon et al.1996). Partial gastrectomy is also a cause for 
reflux gastritis. 
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Mechanism of Chemical Induced Gastritis. 
Bile acid damages the gastric mucosal barrier, allowing hydrogen ions to diffuse 
back into the cells, which are subsequently damaged resulting in gastritis 
(Davenport 1968). Chronic reflux of duodenal content and bile lead to chronic 
superficial gastritis and eventually to chronic atrophic gastritis (Dewar et al.1983). 
The affected mucosa is susceptible to ulceration and there is also evidence that it 
may predispose to gastric carcinoma (Domellof et al. 1976, du Plessis 1965, Gear et 
al. 1971, Keighley et al. 1975). Billroth I partial gastrectomy and truncal vagotomy 
and drainage, result in greater enterogastric reflux because they either destroy or 
bypass the pylorus respectively (Keighley et a1.1975). Long term follow up of 
patients who have undergone partial gastrectomy for benign gastric diseases 
revealed an increase in the incidence of gastric carcinoma (Gear et al. 1971, 
Stalsberg et aU97l). Reflux gastritis in an intact stomach is a controversial entity, 
with some authors stating that the gastritis results from NSAIDs induced damage 
(Frezza et al 2001, Sobala et al. 1990). There is a significant correlation between 
the severity of reflux gastritis and both hypochlorhydria and high bile acid 
concentration in the stomach (Dixon et aI.1986). It might be argued that increased 
alkalinity is more likely to result from long term reduction in G cells and parietal 
cell activity brought about by chronic atrophic gastritis, rather than a short term 
effect of alkaline reflux (Dixon et a1.1986). Cases of hypochlorhydria due to bile 
reflux do not show intestinal metaplasia, which is a feature of chronic atrophic 
gastritis. 
IDstologicai Changes of Chemical Gastritis 
The gastric mucosa shows foveolar hyperplasia, oedema, congestion and smooth 
muscle proliferation in the lamina propria (Dixon et aI.1986). A slight increase in 
the number of chronic inflammatory cells may be observed. If there are no erosions, 
neutrophil infiltration will not be a feature. However these changes are not entirely 
agreed on. Niemela et al (1987) suggested that gastroduodenal reflux may be the 
cause of pre-pyloric ulceration in a mucosa already damaged by H.py/ori (Karttunen 
et a1.l988). Foveolar hyperplasia appears to be the result of excessive cell 
exfoliation from the surface epithelium or of stimulation by cytokines or other 
inflammatory mediators. These changes were first reported in patients with bile 
reflux and subsequently observed after gastric surgery (Dewar et al 1984). Some 
investigators found a poor correlation between bile reflux and the histological 
changes described above (Hoare et al.1978). 
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1.3.2.2 Morphological classification: (Correa et al.1992) 
1.3.2.2.1 Non-atrophic gastritis 
a) Chronic superficial gastritis (SG): The inflammation is in the superficial 
mucosa, predominantly in portions of the mucosa occupied by pits (Correa et 
a1.1988, 1992). 
b) Diffuse antral gastritis (DAG): Typically seen in North America and Western 
Europe. It is confined to the antrum, with easily identified H. pylori. DAG 
may result in duodenal ulcers, probably as a result of increased basal acid 
output and the high response of the parietal cells to stimulation (El Omar et 
aI.1995). 
1.3.2.2.2 Chronic atrophic gastritis. 
a) Diffuse corporal gastritis (DCG): The inflammation involves the whole 
mucosal thickness and is associated with loss of glandular elements. 
b) Multifocal atrophic gastritis (MAG). MAG is prevalent mainly in under-
developed countries. Typically it is patchy in distribution and involves both 
pyloric and fundal mucosa (Correa et a1.1992). H. pylori are sparse. It may 
associated with benign gastric ulcer and carcinoma (Correa et aI.1995). The 
explanation for the difference in the geographic variations is unclear, but one 
possibility is the early age of infection in the developing countries. However 
dietary deficiencies such as vitamin C and high salt consumption are also 
believed to play an important role (Caygill et aI.1996). 
1.3.2.3 Topographical classification: 
Chronic gastritis can be classified as either antral predominant or corpus 
predominant, or by another classification as multifocal or diffuse in distribution. 
1.3.3 Grading Of Gastritis 
H. pylori should be evaluated on the areas where it is usually resides, such as in the 
surface mucus and areas that do not show intestinal metaplasia. A neutrophil 
infiltrate is a universal feature of H.pylori infection. Neutrophils are seen in the 
lamina propria, within the epithelium and in the lumen of glands and foveolae. The 
density of neutophils has been correlated with the extent of mucosal damage and H. 
pylori infection (Correa et al 1992). Neutrophils are a sensitive indicator of the 
presence of H.pylori, and they disappear within days after eradication of the 
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infection (Correa et al 1992). A few mononuclear leukocytes are normal within the 
gastric mucosa. The normal stomach contains 2-5 mononuclear inflammatory cells 
(lymphocytes, plasma cells and macrophages) per high power field (HPF= field 
diameter of 0.44 mm). Plasma cells are absent in the normal gastric mucosa. Some 
observers consider the presence of two plasma cells per high field to be the upper 
limit for normal gastric mucosa (Correa et al 1992). Glandular atrophy is 
manifested by an increase in the distance between individual glands. Grading of 
minor glandular atrophy in the antrum is difficult, because the antrum normally 
contains more connective tissue, than other regions of the stomach. Intestinal 
metaplasia is an indicator for the presence of atrophy. Gastric atrophy usually 
represents an end stage of chronic gastritis (Dixon et al. 1996). Gastric atrophy is a 
precursor for the genesis of carcinoma. 
When reporting gastric biopsies, it is recommended that H. pylori, chronic 
inflammation, neutrophil activity, gland atrophy and intestinal metaplasia be 
evaluated. Chronic inflammation, active inflammation, intestinal metaplasia and 
atrophy can be graded into three grades, mild, moderate and severe (Correa et 
a1.1992). 
1.4 COMPLICATION OF CHRONIC GASTRITIS. 
1.4.1 Intestinal Metaplasia 
Intestinal metaplasia refers to the progressive replacement of gastric mucosa by 
intestinal epithelium and having the light and electron microscopic features of 
intestinal epithelium, of either small or large bowel type, including goblet cells, 
absorptive cells (with brush border), Paneth cells and endocrine cells (Mingazzini et 
a1.1984, RubinbW 1969). Chronic gastritis may be associated with two types of 
metaplasia, intestinal or pyloric metaplasia. Metaplasia is common in chronic 
gastritis and it increases in prevalence with the duration of the chronic gastritis. 
Intestinal metaplasia can be classified into three types according to the type of mucin 
expressed (Appelman 1994). Intestinal metaplasia has been divided into complete 
(type I) and incomplete (type 11). 
Complete intestinal metaplasia (Type 1). The histological features are nearly 
identical to that of the small intestine epithelium with villi and crypts lined by goblet 
cells and absorptive cells with a brush border. Histochemically the mucin present is 
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predominantly sialomucin with or without a small amount of sulfomucin and or 
neutral mucin. (Barwick 1987, Dixon et al 1996, Rothery GA et al. 1985). 
Incomplete intestinal metaplasia. The absorptive cells are absent in this condition. 
Columnar cells with the appearance of gastric foveolar cells are retained. 
Incomplete 1M can be divided histologically into two subtypes: 
a) Type ITa or IT is characterized by the predominance of neutral mucin. There 
are a few absorptive columnar cells secreting neutral and sialomucin. Goblet 
cells containing predominantly sialomucin are also present. 
b) Type llb or ill is characterized by crypts lined by tall columnar cells which 
contain abundant sulphomucin, with a small number of goblet cells that have 
either sialomucin or sulfomucin. (Jass et al. 1981, Silva at al. 1990). 
Sulphomucin differs from sialomucin by positivity for high iron diamine (Born et al. 
1977). Type ill (lIB) metaplasia is believed by some to be closely linked to cancer 
while type I 1M has the lowest risk of gastric carcinoma (EI-Zimmaity et al. 2001, 
Futoshi et a1.1982, Iida et a1.1982, Jass et a1.1979). Others have reported no such link 
between type 1m and carcinoma (Dixon et al. 1986). Some studies showed that 
intestinal metaplasia is not a consistent change, that the type of metaplasia appeared 
to change in both directions and that intestinal metaplasia regresses after H. pylori 
eradication. (Maaroon et al. 1985, Silva et a1.1990). One study showed that on 
follow-up, typing intestinal metaplasia did not predict the pattern in subsequent 
biopsies or the outcome of the patients (Jass et a1.1981). The available data suggest 
that the pattern, extent, and srverity of atrophy with or without intestinal metaplasia, 
are better predictors of the risk of gastric cancer than the subtypes of intestinal 
metaplasia (Jass et al. 1981). 
1.4.2 Peptic Ulcer 
Peptic ulcer is a breach in the epithelial surface of the stomach that has penetrated 
through the muscularis mucosa into the wall of the stomach. Peptic ulcers can be 
acute or chronic. All gastric ulcers, except those which result from treatment with 
NSAIDs, are surrounded by an area of acute and chronic inflammation (Gear et al. 
1971, MacDonald 1973). Most gastric ulcers are accompanied by multifocal atrophic 
gastritis (MAG), while duodenal ulcers are accompanied by diffuse antral gastritis 
(DAG) and not atrophic gastritis (Correa et a1.1992). Some studies showed that 
patients with H pylori infection and duodenal ulcer also have a disturbance of gastric 
function, characterized by an increased release of gastrin by the antral mucosa, and an 
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exaggerated acid response to stimulation by gastrin compared with infected persons 
without ulceration (El-Omar et a1.1995, McGowan et a1.1996). At the edge of all 
ulcers, reactive epithelial changes can occasionally be confused with dysplasia or 
carcinoma. 
1.4.3 Atrophic Gastritis 
Atrophic gastritis is an important pre-cancerous lesion. There are three types of 
chronic atrophic gastritis, including type A, type B and type AB chronic gastritis 
(Glass et a1.1975, Strickland et al. 1973). Type A atrophic gastritis is located in the 
body, associated with achlorhydria, and subsequent bacterial overgrowth. This 
overgrowth enables the Nitrates to be converted into nitritis and N- nitroso 
compounds, which are potent gastric carcinogens, especially for intestinal type gastric 
carcinomas (Reed et al. 1981, Tannenbaum et al. 1983). Type B atrophic gastritis is 
located primarily in the antrum and is associated with normal or hypersecretion of 
gastric acid and peptic ulceration. The most common causes are Hpylorl, exogenous 
and endogenous irritants such as hot drinks, alcohol, tobacco and refluxed bile (Wyatt 
et al. 1988). Type AB atrophic gastritis consists of patchy gastritis in both the antrum 
and body of the stomach. This type of gastritis was noted in populations consuming a 
diet rich in salt, and deficient in fresh fruit and vegetables (Correa 1988). These 
patients have a gradual decrease in gastric pH, with consequential bacterial 
overgrowth. 
1.4.4 GASTRIC DYSPLASIA AND PRIMARY GASTRIC CARCINOMA 
1.4.4.1 Gastric dysplasia. 
Gastric dysplasia is a precanerous lesion and defined as a histopathological 
abnormality in which cancer is more likely to develop than in the normal counterpart 
(Morson et al. 1980). However, not all pre-cancerous lesions necessarily transform 
into cancers. In the gastrointestinal tract, the term dysplasia is applied to disorders of 
growth and differentiation, associated with increased malignant potential. Dysplasia 
implies a neoplastic but non-invasive process, and should be differentiated from 
inflammatory atypia (Jass 1983). Dysplasia is graded on the basis of cytological and 
architectural changes into low and high grade, the latter including carcinoma in-situ. 
A three-tiered system that grades dysplasia into mild, moderate and severe was used 
in the past (Morson et at. 1980). Gastric dysplasia which seen in gastric adenomas 
can morphologically resemble dysplasia seen in colorectal adenomas. Gastric 
dysplasia usually arises in type DB intestinal metaplasia, but also can arise in type I 
(complete) intestinal metaplasia or normal gastric mucosa (Jass and Filipe 1981). 
14 
There are useful criteria in the differentiation of gastric dysplasia and reactive 
changes especially at an edge ofa peptic ulcer that (Owen et al1991) include 
1) Benign lesion with intestinal metaplasia can show nuclear crowding and 
increased mitotic activity at the base of the glands, but toward the surface fully 
mature epithelial cells are identified. 
2) Reactive nuclei are vesicular and rounded with single or double enlarged 
nucleoli, while neoplastic nuclei are hyperchromatic, enlarged, crowded and 
compressed. 
3) In peptic ulceration the inflammation is most severe in the areas of severe atypia. 
Carcinoma may show severe atypia without the presence of inflammation. 
4) The transition between malignant and benign epithelium is abrupt, in comparison 
to inflammatory atypia, which shows a gradual transition from atypia to normal 
appearing epithelium. 
Two variants of gastric dysplasia have been described (Jass 1983). 
1) Type I dysplasia or the adenomatous variant, closely resembles colonic adenomas 
morphologically. In this type, the dysplastic cells are crowded with elongated nuclei 
and abundant cytoplasm. Mucin is minimal within the cytoplasm. The dysplasia can 
be polypoid or flat. The surrounding epithelium may be normal or show intestinal 
metaplasia. Type I dysplasia can be graded into low and high grade dysplasia. Low 
grade dysplasia has simple tubular glands with no obvious architectural distortion, 
lined by cells showing basally located nuclei and sparse mitotic figures. High-grade 
dysplasia shows marked architectural distortion of the glands with branching and 
budding form patterns. There is marked mitotic activity and nuclear stratification. 
This type of dysplasia is usually associated with intestinal type adenocarcinoma. 
2) Type II dysplasia (hyperplastic), has both goblet and columnar cells. The 
cytoplasm is pale and inconspicuous. Nuclei are enlarged, round, vesicular with 
prominent nucleoli. Loss of polarity is not a prominent feature in this type of 
dysplasia. Type II dysplasia arises in a background of incomplete intestinal 
metaplasia. It is associated with high-grade intestinal adenocarcinoma. This type of 
dysplasia that can be difficult to differentiate from regenerative atypia. 
Progression of mild and moderate dysplasia to carcinoma is slow and even rare in 
mild dysplasia, while on the other hand high grade dysplasia is highly predictive of 
subsequent cancer. Mild and moderate dysplasia requires an endoscopic follow up, 
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while severe dysplasia require surgical intervention (Kokkola et al. 1996). Most 
patients who were diagnosed as having high-grade dysplasia of the gastric mucosa on 
examination of gastric biopsy specimens, either had synchronous gastric cancer or 
rapidly developed gastric cancer. Also most cancers that were associated with high-
grade dysplasia, were nearly all early gastric carcinoma and thus potentially curable 
by surgery. (Lansdown et al. 1990). 
There are many differences in the diagnosis of gastric carcinoma made by the 
Japanese and Western pathologists. The Japanese diagnose gastric carcinoma on 
nuclear and architectural changes, regardless of the presence or absence of invasion 
into the lamina propria, while Western pathologists require invasion of the lamina 
propria to diagnose carcinoma (Goldstein and Lewin 1997, Schlemper et al. 1997). 
1.4.4.2 Gastric Carcinoma 
1.4.4.2.1 Epidemiology and biology 
Gastric carcinoma is one of the most common cancers globally (Muir et al. 1987, 
Parkin et al. 1993). It has a high incidence in the developing countries of the 
world, including South Africa and endemic especially in the mixed race 
population of the Western Cape (Dent et a11981, Wyndham 1985). The disease 
occurs rarely before the age of 40, but its incidence increases steadily thereafter 
and peaks in the seventh decade (Fuchs et al. 1995). In the United States the 
disease is 1.5-2.5 more common in African-Americans than in those of 
Caucasian origin (Fuchs et al. 1995.). Gastric carinoma is a major killer world-
wide and remains the second 
most common cause of cancer-related deaths in the world (Whelan et al. 1993). 
Hpylori is a well-known predisposing factor for the development of gastric 
carcinoma and one study suggested that 60% of gastric adenocarcinomas are 
attributed to Hpylori infection, which implies that the incidence of gastric 
carcinoma could be reduced by 60% if H pylori was eradicated (parsonnet et al. 
1991). Gastric carcinoma is believed to arise via a multi-step process that 
includes chronic gastritis, gastric atrophy usually with intestinal metaplasia, and 
finally dysplasia (Correa et al. 1988, 1992, EI-Zmaity et al. 2001). Atrophic 
gastritis, intestinal metaplasia and dysplasia are considered precancerous lesions 
(Testoni et al. 1987). 
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1.4.4.2.2 Pathological features 
More than 90% of gastric cancers have been reported to be adenocarcinomas 
(Fuchs et al. 1995). The most widely used classifications for gastric cancer are 
that of Lauren (1965), and the World Health Organization (WHO) 
classifications. 
According to the WHO classification of gastric carcinoma the disease includes 
adenocarcinoma in-situ/severe dysplasia, adenocarcinoma, papillary 
adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, signet-
ring cell adenocarcinoma, adenosquamous carcinoma, squamous carcinoma, 
small cell carcinoma and undifferentiated carcinoma (Watanabe et all 1991). 
Lauren classified gastric carcinoma into intestinal and diffuse type (Lauren 
1965); each is considered as a separate pathological entity, with different 
epidemiological, clinical, pathological and biological characteristics (Lauren 
1965). Occasionally gastric carcinomas show combined features of diffuse and 
intestinal carcinomas (Lauren 1965, Oota and Sobin 1977). 
Intestinal type adenocarcinoma is usually ulcerated and occurs in the distal 
stomach. Histologically, the tumour is composed of cohesive neoplastic groups 
of glands that resemble colonic adenocarcinoma. The majority of gastric 
carcinomas arise in a non-polypoid mucosa, in contrast to the colonic 
carcinomas, which arise in adenomatous polyps. 
Intestinal type gastric adenocarcinoma is more common in males and affects 
those of an older age group, and arises in a background of intestinal metaplasia 
and is closely related to exogenous factors as Hpy/ori, nitrosation and bile reflux 
(parsonnet et al. 1991). Intestinal type adenocarcinoma has better prognosis than 
the diffuse type. 
Diffuse type adenocarcinoma occurs in younger patients and spreads diffusely 
throughout the stomach. The tumour is composed of solitary or small clusters of 
non-cohesive neoplastic cells without gland formation. It is thought that diffuse 
type adenocarcinoma is governed by endogenous host-related factors and genetic 
susceptibility, and is not preceded by known pre-cancerous alteration (Howson et 
al. 1986). 
17 
Early gastric carcinoma is the term applied to invasive carcinoma confined to the 
mucosa or submucosa (Day and Morson 1978, Seifert et a1. 1975, Evans et a1. 
1987). It differs from carcinoma in-situ, which does not penetrate the basement 
membrane and has no metastatic potential. Early gastric carcinoma is mainly 
identified in the distal stomach along the lesser curvature. It may have 
metastatic potential. The five-year survival rate of early gastric cancer is over 
90% (de Dombal et al. 1990). 
1.4.4.2.3 Risk factors for gastric carcinoma 
1) H. pylori infection 
2) Chronic atrophic gastritis 
3) Intestinal metaplasia 
4) Cigarette smoking 
5) Low socioeconomic status 
6) Low consumption of fruit and vegetables 
7) Consumption of salted, smoked or poorly preserved foods 
8) Pernicious anemia 
9) Partial gastrectomy for benign gastric conditions (usually peptic ulcer) 
10) Gastric adenomatous polyp 
11) Hereditary non-polyposis colon cancer syndrome 
Pernicious anemia is associated with a 2-3 folds increased risk of gastric cancer 
(Hsing et a1. 1993). Patients infected with H.pylori have a 3-6 fold higher risk of 
gastric carcinoma (Parsonnet et a1. 1991). The malignant potential of 
adenomatoyus polyps of the stomach is related to size of the polyp and the grade 
of dysplasia (Nakamura et a1. 1985). Consumption of large amount of salted food 
may lead to atrophic gastritis. The association of H.pylori infection with 
carcinoma is similar regardless of the histological type, although other studies 
based on the histological detection of H.pylori have showed the prevalence to be 
lower in the diffuse type adenocarcinoma in comparison with the intestinal type 
adenocarcinoma (Buruk et a1. 1993). Gastric carcinomas located in the cardia are 
less frequently associated with H.pylori compared with other tumor locations 
(Hansson et a1. 1993, 1995, Normura et a1. 1991) and it has been suggested that 
environmental factors playa major role in the aetiology of intestinal type gastric 
carcinoma, while the diffuse type may have a primary genetic etiology (Howson 
et a1. 1986). Type IIB 1M is noted to be significantly more frequent in patients 
with adenocarcinoma than with benign ulcers, as well as more prevalent in 
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stomach with intestinal type of adenocarcinoma than with diffuse type of 
adenocarcinoma (Segura and Montero 1983). 
1.4.4.2.4 Molecular features of gastric carcinoma. 
Gastric carcinomas show allelic deletion of the MCC gene (mutated in colonic 
cancer) in 33% of patients, APC gene (adenomatous polyposis coli) in 34% of 
patients and p53 tumor suppressor gene in 64% of patients (Rhyu et al. 1994). 
Patients with intestinal type of adenocarcinoma have an increased frequency of 
over expression of epidermal growth factor receptor, erbB-2 and erbB-3 (Wright 
et al. 1993). 
1.4.4.2.5 Prognostic factors for gastric carcinoma 
The overall 5-year survival rate for gastric carcinomas was 14% in one American 
Study (Houben et al. 1995) and less than 10% overall in the United Kingdom (de 
Dombal et at. 1990). 
1) The stagie of gastric carcinoma: is the most important prognostic factor. 
Gastric carcinoma is staged according to the depth of the invasion of the 
tumor cells and the presence or absence of metastasis in the regional lymph 
nodes and other organs. The American Joint Committee incorporates the 
TNM classification of gastric carcinoma (Felming and Cooper 1997). 
Intestinal type adenocarcinoma has a 26% five-year survival, while diffuse 
type adenocarcinoma has 16% five year survival rate (Wanebo et at. 1993). 
TNM Staging of gastric carcinoma. Please see appendix 1. 
2) Degree of differentiation: Tumors with poor differentiation have a 
diminished survival rate. 
3) Genetic alteration. Tumors with abnormal DNA content and proto-
oncogenes of tumor suppressor genes are associated with a diminished 
survival rate (Uchino et al. 1993). 
4) Clinical and serology. Adverse prognostic factors include age more than 70 
years, Carcinoembryonic antigen (CEA) more than IOng/ml and CA19-9 
more than 37 J.l g/ml (Kirkwood et at. 1997). 
1.4.4.2.6 Surgical treatment of gastric carcinoma. 
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Gastrectomy with lymph·node clearance for gastric carcinoma offers the only 
chance for cure. Partial gastrectomy with resection of the adjacent lymph·nodes is 
sufficient for distal carcinoma. A randomized comparison between total and 
partial gastrectomy showed a higher rate of morbidity and mortality after total 
gastrectomy (Gouzi et al. 1989). Resection of the primary tumor is usually 
palliative, but offers good symptomatic relief. In the absence of ascites and 
extensive metastatic disease, patients who are thought to be surgically incurable 
should be considered for palliative surgery (Thompson et al 1993). This can 
relieve pain, bleeding and obstruction. 
Early gastric carcinoma can be cured surgically, with a cure rate of 89·93% if 
lymph nodes are free of tumour and 80%·91% if the lymph nodes are involved 
(Johansen 1976). 
1.5 GASTRIC REMNANT CARCINOMA 
1.5.1 Definition 
Gastric remnant carcinoma (GRC) was first described by Balfour in 1922. GRC, also 
known as "gastric stump carcinoma", is defined as gastric carcinoma, which occurs in 
patients after gastric operation for benign gastric disease (Klarfeld and Resnick 1979). 
It was defmed initially as any carcinoma that had developed in a gastric remnant. Later 
it was stipulated that at least five years must have elapsed after partial resection of the 
stomach in order to eliminate the possibility that the original resection had been a 
malignant disease and that the tumour in the gastric remnant was a recurrence 
(Welvaart and Carsick 1982). 
1.5.2 Incidence 
GRC occurs in 1·9% of patients operated on for benign gastric disease (Mason et al. 
1988, Helsingen and Hillstad 1956, Boren et aL 1980, Fisher et al. 1983, Newman et al. 
1997). Some investigators have shown an association between surgery for peptic ulcer 
and subsequent risk of gastric cancers (Stalsberg and Taksdal 1971, Pickford et al. 
1984, Molloy and Sonnenberg 1997, Viste et al. 1986, Schrumpf et al. 1977), while 
other studies showed no association, and have reported a risk similar to that in the 
general population (Kalina et al. 1983, Sandler et aI. 1984, Fischer et al. 1984, Clark et 
al. 1983, Schafer et al. 1983, Wlarfeld et aI. 1997). 
There appears to be a IS-year protective interval of low incidence of carcinoma after 
which the incidence steadily increases (Domellof et al. 1977). There is a significant 
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increased risk of GRC twenty years after surgery (Caygill et at. 1987). The time 
interval since the initial surgery is the most important risk factor for GRC. There is 
also a geographic difference in the relative risk of GRC. The risk of GRC in Japan, a 
country that has one of the highest incidences of PGC, is low when compared with the 
figures that are available in Europe and the United States (Tersmette et al 1991). Some 
have also observed an increased risk of cancers of the oesophagus, colon, pancreas, 
breast and lung after peptic ulcer surgery (Wat et at. 1984). Although some studies 
show no clear relation between site of the original disease (duodenal vs. gastric ulcer) 
and subsequent development of carcinoma (Stalsberg and Taksdal 1971, Klarfeld and 
Resnick 1979), others showed that only surgery for gastric ulcer but not for duodenal 
ulcer was associated with a risk of GRC (Molloy and Sonnenberg 1997). The risk of 
GRC is greater in patients treated for GU than those treated for duodenal ulcer 
(Welvaart and Carsick 1982, Molloy and Sonnenberg 1997). 
Several observers have studied post surgical patients prior to the development of GRC, 
and the most common changes seen are atrophic gastritis, intestinal metaplasia and 
cystic dilatation of gastric glands. These changes occur as early as three months post 
operatively (Gjeruldsen et at. 1968, Domellof et al. 1977). 
1.5.3 Aetiology of GRC 
Gastric resection appears to be associated with an increased risk for gastric cancer, and 
this risk rises with the length of the time since surgery (Molloy and Sonnenberg 1997). 
Surgery results in gastric hypoacidity, which leads to bacterial overgrowth with a 
consequent production of carcinogens. A hypothesis involving nitrite and N-nitroso 
compounds has been suggested (Schlag et al. 1980). Bile reflux is thought to play an 
important role in the aetiology of GRC and some studies in animal models showed that 
pancreatico-duodenal secretion reflux is an important factor in the malignant process 
(Mason et al 1986,1988). Partial gastrectomy creates a new microenvironment, which 
favours the development of cancer. GRC appears to evolve as the end result of a series 
of mutoganic cell transformations affecting the gastric mucosa over a prolonged period 
of time. Antrectomy is thought not only to decrease acid production but also enhances 
the development of gastric atrophy (Tatsuta et al 1982). Regurgitation of bile and 
pancreatic enzymes after Billroth IT surgery was suggested to be due to the 
reconstruction, decrease in blood supply and altered enervation at the site of 
anastomosis (Ruddell et at. 1976, Cheung 1987). Other studies showed no association 
between reflux and mucosal changes (Domellof et at. 1977). The possible sequence of 
GRC is bile reflux inducing irritation, decreased resistance of the gastric mucosal 
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barrier and gastritis, with subsequent absorption of potentially carcinogenic compounds 
from intestinal contents (Klarfeld and Pesnick 1979). ORe has a similar histogenetic 
pathway to that for POC, i.e., via atrophic gastritis and intestinal metaplasia, 
particularly of type lIB intestinal metaplasia. Operated stomach shows hypochlorhydia 
and achlorhydia with increased pancreatic and bile reflux resulting in atrophic gastritis 
and intestinal metaplasia in the gastric stump (Domellof et al. 1977, Pickford et al. 
1984, Savage et al. 1979). It is postulated that high gastric acidity associated with 
Billroth I and II surgery, may be conducive to the proliferation of anaerobic bacteria 
that colonize the stomach and transform dietary or endogenous nitrates to nitrites. 
These substances produce additional N·nitroso compounds, which act as carcinogens 
(Helsingen and Hillestad 1956). Chemical atrophic gastritis in the gastric remnant 
leads to colonization of the mucosa by bacteria, which may include H.pylori (Elder and 
Knight 1991). H.pylori is not found to have a significant association with ORe 
(Greene 1996, Johannesson et al. 2003). Yamamoto et al. in 1994 showed significant 
association of Epstein·Barr virus (EBV) and ORe. In·situ hybridization in a study 
done by Nishikawa et al. (2002) demonstrated that 42% of patient of ORe were 
positive for EBV and all EBV positive ORe were poorly differentiated carcinomas. 
Many studies showed a predilection of the stomal site for subsequent development of 
ORe. Most studies suggested that ORe is most likely to occur in the middle and antral 
portion of the stomach near the anastomosis site with the bowel (Freedman and Berne 
1977, Morgenstren et al. 1973, Klarfeld and Resnick 1979). 
1.5.4 Histological Types and Prognosis of GRC. 
ORe can be of the intestinal, diffuse or mixed type according to the classification of 
Lauren (1965) (Domellof et al. 1977, Pickford et al. 1984, Savage et al. 1979). The 
histological type and histochemical mucin profile of ORe parallel those recorded in 
POC (Stemmerman and Brown 1974). Histologicaly the mucosa of gastric remnant 
usually shows chronic gastritis, accompanied by atrophy, foveolar hyperplasia, 
intestinal metaplasia and cystic dilatation of the glands (Harmon et al 1981, Ritchie 
1984). The histological features seen after partial gastrectomy resemble those of pre· 
malignant mucosa in an intact stomach. Follow·up studies may establish the 
predictive value of these precursor lesions in development of the POC (Tersmette et 
al 1995). Prognosis of ORe was recorded as poor in some studies in which an overall 
survival is reported to be less than 10%; this has been attributed to the late stage at 
presentation (Morgenstern et al. 1973, Orlando and Welsh 1981). Endoscopic follow 
up and early diagnosis of ORe resulted in more optimistiC survival data (Newman et 
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at. 1997). Follow up starting 10-15 years after surgery, preferably by endoscopy and 
multiple biopsies is recommended, because endoscopy is superior to radiology in the 
diagnosis of early carcinoma (Domellof et at. 1977). Annual screening, especially of 
patients who are at least 15 years post-gastric resection, using flexible endoscopy and 
multiple random biopsies may detect early GRC and lead to curative gastrectomy 
(Greene 1996). One study reported significantly better survival for gastric remnant 
cancer patients in stage I or II disease compared with similar stage primary proximal 
gastric carcinoma (Newman et at. 1997). Early diagnosis is emphasized (Klarfeld 
and Resnick 1979) and the prognosis depends on the stage of the disease when 
surgery is performed (Bogomoletz et at. 1985, Thorban et at. 2000). A five-year 
survival rate of up to 47% could be achieved in some studies (pointner et al 1988, 
Gianello et at. 1983). Surveillance of patients who had partial gastrectomy, with 
endoscopy and multipule gastric biopsies may provide the means to diagnose GRC at 
an early stage (Safatle-Ribeiro et at. 2001), but cost beneficial ratio of the 
surveillance should be considered and studied. 
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CBAPTERTWO 
MATERIALS AND METHODS 
2.1 AIMS OF THE STUDY 
1. To describe the morphology of gastric remnant carcinoma (GRC) and 
the pathology of the adjac;ent normal mucosa. 
2. To determine the histochemical and immunohistochemical mucin 
profile of GRC. 
3. To compare the mucin profile of GRC with the profile of primary 
gastric carcinoma (pGC) and with data of a previous study performed 
in this department and with the results available in the literature. 
4. To determine any prognostic significance of the mucin expression in 
GRC. 
2.2 METHODS 
In this study histochemical and immunohistochemical methods were used to 
determine the mucin profile in GRC, PGC diffuse type, PGC intestinal type 
and in normal gastric tissue. 
.. 
2.2.1 Case selection 
Gastric tissue from fifty patients was used in this study. Paraffin embedded 
tissue specimens were obtained from archival material in the Department of 
Anatomical Pathology, Groote Schuur Hospital. Twenty cases of GRC 
diagnosed between 1984 and 2001 were identified from the clinical records 
" (one case was subsequently excluded from this study because the tissue 
remaining in the paraffin block showed only intraepithelial malignancy but no 
evidence of the invasive malignancy that was seen in the original sections). 
The material included twelve biopsies and seven resection specimens. The 
original haematoxylin and eosin (H&E) stained sections were reviewed and 
confirmed by a second opinion. The tumours were classified according to the 
Lauren's classification (Lauren 1965), into intestinal, diffuse or mixed type of 
adenocarcinoma. 
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Twenty cases of PGC were included in the study; of which ten were PGC 
intestinal type and ten PGC diffuse type. All the intestinal adenocarcinoma 
specimens and five of the diffuse adenocarcinoma specimens were obtained by 
partial gastrectomy and total resection respectively, while diffuse tumors were 
biopsy specimens. The specimens were identified through a computer search 
between 1999 and 2001 and were retrieved from the Anatomical Pathology 
Department files; the cases were selected randomly. 
Ten cases of the normal histology were selected from gastric biopsies that had 
been SNOMED coded as normal material. Fifty cases coded as normal gastric 
tissue were reviewed and ten were selected as a control material. Cases were 
considered normal after exclusion of acute gastritis, chronic gastritis, 
Helicobacter pylori, metaplasia, atrophy or dysplasia. Six of the biopsies were 
taken from patients with non-ulcer dyspepsia, and who underwent endoscopy 
and gastric biopsy. Three of the patients had metastatic carcinoma, for whom 
endoscopy was used to exclude a PGC; a biopsy was performed despite the 
absence of tumour and shown to be negative for tumour. This last specimen 
was also used as a control in a previous carcinoma study (Taylor et aI1998). 
This study was approved by the Research Ethics Committee of the Faculty of 
Health Sciences, University of Cape Town (ERC NO: 026/2002) 
2.2.2 Histology. 
The updated Sydney Classification System was used for the grading of 
gastritis, H.pylori infection, atrophy and intestinal metaplasia. All carcinomas 
were classified according to the Lauren classification (1965). Where possible, 
the protocol for the staging system of gastric carcinoma, as defined by the 
American Joint Committee on Cancer and the International Union Against 
Cancer (Compton et a1. 1998) was employed. 
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2.2.3 Histochemistry 
Paraffin-embedded tissue blocks were cut to provide four /-Lm thick sections on 
which the histochemical and immunohistochemical stains were performed. 
Sections were stained by H&E, Giemsa, periodic acid-Schifflalcian blue pH 
2.5 (pAS/AB 2.5) and high iron diamine (HID). 
The combined alcian blue-periodic acid-Schiff (p ASI AB) technique was used 
to distinguish between acidic and neutral mucins. The sections were washed 
in distilled water, treated with alcian blue solution for 15 minutes and washed 
well in distilled water. Sections were then treated with periodic acid solution 
for 15 minutes and then washed with water. Sections were subsequently 
treated with Schiffs reagent for 15 minutes and then washed again with water. 
Sections in the last steps were dehydrated through graded ethanol to xylol and 
mounted in a synthetic resinous medium and cleaned. PAS stains neutral 
mucin magenta. AB pH 2.5 stains acidic mucin (sialomucin) and most 
sulphated mucins blue (Table 2.1). 
Sections for HID were de-paraffinized and washed with distilled water and 
treated with diamine-ferric chloride solution in a Coplin jar for 16-18 hours. 
The sections were washed well in distilled water and then stained with alcian 
blue solution for 15 minutes, followed by washing, dehydration and mounted 
in resin. HID stains sulphated mucin black and non-sulphated mucin blue 
(Table 2.1) (Bancroft & Cook. 1994). 
Giemsa stain was used to detect Hpylori. Sections were washed with water 
and treated with newly prepared fresh 2% Giemsa solution for 30 minutes and 
followed by washing in water, dehydration and mounting. Hpylori appear 
dark purple against a lighter purple background. 
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Table 2.1 Histochemical stains for mucin 
Neutral Acidic 
Stain Sulphomucin Sialomucin 
mucin mucin 
PAS Red 
- - -
AB pH 0.5 blue blue 
- -
ABpH2.5 blue blue blue 
-
P AS/ AB pH2.5 red blue blue blue 
Mucicannine/ AB 
red blue blue blue 
pH2.5 
HID/ AB pH 2.5 
-
blackibrown blue 
-
OrceinlAB pH 2.5 brown blue 
- -
Aldehyde-Fuchsin-
deep purple blue 
AB - -
Aluminium sulpate-
blue red 
AB - -
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2.2.4 Immunohistochemistry 
Antibodies used in this study were against, MUCl, MUCIC, MUC2, MUC3, 
MUC4, MUC5AC, MUC5B, MUC6 and MUC7. 
Table 2.2. Mucin core peptide antibodies 
Mucin gene Type Clone Source Dilution Method 
MUCI Mouse Ma695 Novocastra, UK 11100 Envision 
MUCIC Mouse Ma552 Novocastra, UK 11100 Envision 
MUC2 Mouse Ccp58 Novocastra, UK 11100 Envision 
MUC3 Rabbit pAb* Biomedia, USA 11500 Envision 
MUC4 Chicken pAb Prof. Ro** 11200 Avidin 
Biotin 
MUC5AC Mouse CLH2 Prof. Ro** 11100 Envision 
MUC5B Chicken pAb Prof. Ro** 11400 Avidin 
Biotin 
MUC6 Mouse CLR5 Novocastra, UK 11100 Envision 
MUC7 Chicken pAb Prof. Ro** Avidin 
Biotin 
* = Polyc1onal antibodies 
**= Personal gift from Professor Samuel B. Ro. 
Link Antibody = Goat anti-chicken at 11200 dilution from Vector Laboratories 
See (Appendix 2) for the supplier of the antibodies used in this study. 
Four mm thick sections were cut and placed on glass slides coated with 3-
aminopropyltri-ethoxysilane. Sections were heat-fixed for 30 minutes at 600C, 
and then de-waxed and re-hydrated. Endogenous peroxidase activity was 
quenched with a 1 % hydrogen peroxide methanol solution for 15 minutes at 
room temperature. Sections were washed three times in phosphate buffered 
saline (PBS) and then micro-waved in citrate buffer (pR 6.00) for 10 minutes. 
Each section was stained immuno-enzymatically in a humidity chamber using 
a modified three-step peroxidase conjugated avidin-biotin method. Non-
specific binding was blocked with non-immune serum (swine, rabbit or goat) 
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at a 1 :20 dilution for 10 minutes. After incubation with each antibody, 
sections were washed thoroughly in PBS. Sections were subsequently 
incubated with 1 :250 dilutions of biotinylated rabbit-anti-mouse and swine 
anti-rabbit (Dako, Copenhagen, Denmark), or 1 :500 rabbit-anti-chicken 
(Biogenesis, Pool, UK) antibody for 30 minutes at room temperature and then 
with a 1 :500 dilution of strep-avidin HRP (Dako, Denmark) for 30 minutes. 
After washing, peroxidase activity was detected using 3.3 diaminobenzidine 
(Sigma, St Louis, USA) as a chromogen and hydrogen peroxide as the 
substrate. After 10 minutes, sections were washed to arrest the reaction and 
counterstained with haematoxylin, blued in Scott's solution and then washed 
in tap water. Sections were then dehydrated through graded ethanols to xylol 
and mounted in a synthetic resinous medium. When the Envision detection 
system was used, primary antibodies were applied for 30 minutes. Slides were 
then rinsed with PBS. The Envision reagent was applied for 30 minutes and 
the peroxidase activity was determined as above. 
Positive immunohistochemical staining was either cytoplasmic, or 
membranous or both. Immunoreactivity was graded as negative (-), weak 
positive (+), moderate positive (++) and strong positive (+++). A specimen 
was considered positive if immunoreactive cells were found in at least 5% of 
the low power field (10 x objective) (Ho et al. 1993). The percentage of cells 
with positive staining was reported as 0%, 25%, 50%, 75% and 100%. 
Positive staining was reported as the percentage of positive cells in proportion 
to the total cell mass. Positive controls were taken from nonnal tissues known 
to express the relevant antibody and an internally built positive control was 
also used. 
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CHAPTER THREE 
RESULTS 
3.1 Morphology of the Tumours 
Out of the nineteen patients of gastric remnant carcinoma (GRC), fourteen 
were male and five were female, ranging from 45 to 78 years old. According 
to Lauren's classification eleven of the tumours were of the intestinal type, six 
of the diffuse type and two mixed gastric carcinoma (Table 3.1, Figure 3.lA 
and 3.1 B). The tumours ranged from early to advanced gastric carcinoma and 
from moderate to poorly differentiated adenocarcinoma. 
There were eight male and two female patients with primary gastric carcinoma 
(PGC) of the intestinal type, and six male and four female patients with PGC 
of the diffuse type. Patients of both groups were between 48 and 84 years old. 
The tumours also ranged from early to advanced gastric carcinoma and from 
moderate to poorly differentiated adenocarcinoma. 
Table 3.1 Types of GRC as defined by the classification of Lauren 
Lauren's classification No of cases 
Intestinal 11119 58% 
Diffuse 6/19 32% 
Mixed 2/19 10% 
3.2 Helicobacter pylori 
The results are summarized in Table 3.3. An assessment of H pylori infection 
could not be done in three cases of GRC because of the absence of gastric 
mucosa. Two cases of GRC showed mucosa adjacent to the tumour exhibiting 
intestinal metaplasia with no normal gastric mucosa. Only three of the total 
number of 19 specimens of GRC showed mild to moderate number of H 
pylori, of which two cases showed focal intestinal metaplasia. The Hpylori 
organisms were seen on the surface of the non-metaplastic mucosa (Figure 
3.2). 
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Three out of ten cases of PGC intestinal type showed the presence of mild to 
moderate number of H pylori. Of these three cases, two showed foci of 
intestinal metaplasia. The organisms were not present on the areas of 
metaplasia. Two of the ten cases ofPGC diffuse type showed the presence of 
mild to moderate number of Hpylori. 
3.3 Gastritis 
Although most cases of gastric carcinoma showed gastritis, only a small 
number showed the presence of H pylori (Table 3.2). Gastritis was seen in 
the non-turnourous gastric mucosa in 12 specimens of GRC, mainly of the 
chronic or active chronic type. The severity of the gastritis ranged from that 
of mild to moderate. Two of the H pylori negative GRC cases showed the 
presence of marked reactive lymphoid follicles, highly suggestive of previous 
infection with H pylori (Genta et a1 1993). Nine of the PGC intestinal type 
and eight of the PGC diffuse type specimens showed gastritis, predominantly 
of the chronic type. Lymphoid follicles were present in two H pylori negative 
PGC intestinal type specimens. In accordance with the criteria used in the 
selection of the normal gastric biopsies, none showed significant inflammatory 
cell infiltrate or lymphoid follicles. 
Table 3.2 Histopathological changes in the different study groups 
Histology GRC PGC intestinal PGCdiffuse 
Intestinal metaplasia 11119 (58%) 8/10 (80%) 4/10 (40%) 
Atrophy 9/19 (47%) 6/10 (60%) 7/10 (70%) 
H.pylori 3/19 (16%) 3/10 (30%) 2/10 (20%) 
Chronic gastritis 12/19 (63%) 9110 (90%) 8110 (80%) 
GRC= Gastric remnant carcmoma, PGO= Pnmary gastric carcmoma 
3.4 HISTOPATHOLOGY AND HISTOCHEMICAL MUCIN PROFILE: 
3.4.1 Normal gastric mucosa 
All of the ten normal gastric mucosa specimens expressed neutral mucin, and 
none of them expressed acidic mucin. 
31 
3.4.2 Intestinal Metaplasia (1M) 
Gastric remnant carcinoma. Eleven of the nineteen of these specimens 
displayed 1M, whilst in five specimens there was no 1M. Three biopsy 
specimens consisted only of tumour without adjacent mucosa (Table 3.3). 
Seven of the eleven cases with 1M showed villi, lined by goblet cells positive 
for alcian blue, and PAS/AB negative columnar cells with brush border, in 
keeping with the diagnosis of complete intestinal metaplasia (Figure 3.3 a, b). 
Three of these seven cases also showed small foci of incomplete 1M (Type II) 
of which two were Type 1m 1M and the other Type lIA 1M. Seven of the 
eleven 1M specimens showed the presence of goblet cells interrupted by 
columnar cells that stained positive for neutral and acidic mucin, in keeping 
with Type II 1M (Figures 3.4 a, b). Three of the seven cases showed Type IIA 
1M (Figure 3.4 c), with neutral mucin in the columnar mucosa and no evidence 
of sulphomucin. The other four cases of incomplete 1M showed columnar 
cells with mucin secretion and significant staining for sulphomucin, indicating 
the presence Type 1m 1M (Figure 3.4 d). Sulphomucin positive 1M was 
present only in the intestinal type GRC (30%), while none of the diffuse type 
GRC expressed Type 1m 1M. 
Table 3.3. Intestinal metaplasia in the different study groups. 
GRC PGC 
IC DC Mixed IC 
Gastric mucosa no OlIO (0%) OlIO present 1111 9% 2/6 33% 0/2 0% 
Intestinal 9/10 (90%) 4/10 
metaplasia SilO SO% 2/4 50% 112 50% 
Type I 5/10· 50% 114 25% 112 50% 5110" (50%) 3/10 
Type IIA 2/10 20% 114 25% 0/2 0% 3/10 (30%) 
Type 1m 3/10 30% 0/4 0% 112 50% 3/10 (30%) 
• Three cases of GRC showed predominantly Type I with focal Type II 1M . 
•• Two cases of PGC intestinal type showed predominantly Type I and focal 
Type 111M. 
, 
1110 
OlIO 
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DC 
(0%) 
(40%) 
(30%) 
(10%) 
(0%) 
PGC intestinal type. Nine of the ten cases (90%) of PGC intestinal type 
showed the presence of 1M of which five were of the complete type. Two of 
these five cases also showed small foci of incomplete 1M. Six cases of 
intestinal type adenocarcinoma showed the presence of incomplete 1M. Three 
cases (30%) showed no sulphomucin staining in keeping with Type IIA and 
three cases (30%) showed the expression of sulphomucin in keeping with 
Type lIB IM (Table 3.3). 
PGC diffuse type. Four often cases ofPGC diffuse type showed 1M; of which three 
(30%) were complete 1M, and one Type IIA 1M. 
3.4.3 Mucin profile in tumour cells of gastric carcinomas. 
GRC. In the GRC group there were eleven intestinal, six diffuse and two 
mixed type adenocarcinomas in accordance with the Lauren system of 
classification. Evaluation of the types of mucin expressed by the tumour cells 
is summarized in Table 3.4. All of the intestinal type adenocarcinoma 
specimens showed weak neutral mucin staining in tumour cells, while six 
(55%) were also positive for acidic mucin, three of which strongly expressed 
sulphomucin within the tumour cells. The expression of neutral mucin was 
stronger in 5/6 specimens of diffuse adenocarcinoma than that in the intestinal 
adenocarcinoma. Three of these five specimens were positive for acidic 
mucin (Figure 3.5), two of which stained strongly for sulphomucin. 
Table 3.4 Histochemical type of mucin in tumour cells of GRC- and PGC 
ORC PGC 
ORCtotal intestinal diffuse mixed intestinal diffuse 
N 19 11 6 2 10 10 
Neutral 17 (89%) 11 (100%)* 5 (83%) (50%) 10/10* (100%) 9110 
Acidic 9 (47%) 6 (55%) 3 (56%) 0 (0%) 1110 (10%) 7/10 
5 (26%) 3 (2'7010) 2 (33%) 0 (0%) 1110 (10%) 6/10 
* all staining was weak 
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(90 
(70%) 
(60%) 
PGC intestinal type. The intestinal type of adenocarcinomas were moderately 
to poorly differentiated. All cases showed weak neutral mucin staining within 
the tumour cells (100%). Only one tumour (10%) showed acidic staining, 
which was positive for sulphomucin (Table 3.4). 
PGC diffuse type. Nine of the ten cases (90%) showed moderate to marked 
neutral mucin staining in the tumour cells while 7110 (70%) showed the 
expression of acidic mucin. Six cases (60%) showed moderate to strong 
sulphomucin staining in the tumour cells (Figure 3.6). In this study, the 
tumour cells of PGC diffuse type showed higher proportion of strong 
sulphomucin 6(0%), than in the PGC intestinal type (10%). 
3.5 IMMUNOHISTOCHEMISTRY 
The results are summarized in Table 3.5 
Table 3.5. Immunohistochemistry 
Normal GRC PGC 
IC DC mixed iPIC PDC 
no of cases 10 11 6 2 10 10 
MUCI 10 (100%) 4 (36%) 1 (17%) 2 (100%) 7 (70%) 3 
MUCIC 10 (100%) 6 (55%) 0 (0%) 1 (50%) 7 (70%) 4 
MUC2 0 (0%) 2 (18%) 1 (17%) 0 (0%) 4 (40%) 4 
MUC4 10 (100%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 
MUC5AC 10 (100%) 5 (45%) 2 (33%) 1 (50%) 2 (20%) 6 
MUC5B 0 (0%) 0 (0%) 1 (17%) 0 (0%) I (10%) 0 
MUC6 5 (50%) 0 (0%) 0 (0%) 0 (0%) 2 (20%) 0 
Note: because of a problem with the MUC3 antibody the results of staining for 
MUC3 are not included in this table (see appendix 3). 
MUC1: MUC1 consistently showed moderate to strong (+++) positive staining 
in all ten (10/10) nonnal gastric biopsies. The staining was in the parietal 
cells only (25-50% the cells) and was both cytoplasmic and membranous in 
distribution (Figure 3.7 A). The surface mucosa was always negative. The 
gastric mucosa adjacent to the gastric carcinomas showed positive MUC1 
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(30%) 
(40%) 
(40%) 
(0%) 
(60%) 
(0%) 
(0%) 
staining only in the parietal cells, similar to the results seen in normal gastric 
mucosa. 
Four out of eleven (36%) of the intestinal type GRC and 1/6 (17%) of the 
diffuse type GRC showed positive staining for MUCl. MUCI positivity was 
strong (+++) and seen in 50-75% of the tumours (Figure 3.7B). Seven out of 
ten specimens of PGC intestinal type showed strong membranous and 
occasionally cytoplasmic staining in the tumour cells (Figure 3.7C), whilst in 
3/10 cases of PGC diffuse type, there was strong cytoplasmic and 
membranous staining in 25% of tumour cells. 
MUCI C: All normal gastric biopsies showed cytoplasmic and membranous 
positive staining in the parietal cells. The surface mucosa and the superficial 
mucus cells of the foveolae were negative for MUCIC. Six cases (55%) of 
intestinal type showed strong membranous and luminal staining for MUC 1 C; 
none (0%) of the diffuse type GRC expressed MUCIC. MUCIC was positive 
in 7/10 (70%) of PGC intestinal type, the staining being localized in the 
membrane, cytoplasm and occasionally in the lumen of the glands. Four out 
often (40%) ofPGC diffuse type expressed MUCIC. 
MUC2: MUC2 staining was absent in all normal gastric biopsies, but 
consistently showed moderate staining of the cytoplasm in the goblet cells of 
the 1M of the different types of gastric carcinoma (Figure 3.8A). Two out of 
eleven (18%) of intestinal type GRC (Figure 3.8B) and 116 (17%) of diffuse 
type GRC showed strong cytoplasmic positive staining for MUC2 in 25-50% 
of the tumour cells. Four out of ten (40%) of PGC intestinal type and 4110 
(40%) ofPGC diffuse type showed moderate to strong cytoplasmic staining in 
50% of the tumour cells. 
MUC3: Immunostaining with an antibody to MUC3 (Biomeda) was tried 
twice. The results of the first attempt were rejected because of unexplained 
positivity seen as diffuse and moderately intense cytoplasmic staining in the 
deep glands of all normal gastric biopsies. Forty percent of PIC showed 
moderate positivity in less than 25% of the tumour cells, while GRC and PDC 
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were negative. The staining was repeated using a second antibody that was 
also supplied by Biomeda; all sections showed unexplained background 
staining and the stain did not work on a known positive control. Please see 
Appendix 3.1 for correspondence with the supplier. 
MUC4: All (100%) normal gastric biopsies showed mild positive staining in 
basal mucous glands; positive staining was also seen in the residual normal 
basal glands in the mucosa adjacent to the different types of gastric carcinoma. 
Surface and neck epithelium in normal gastric mucosa and in mucosa adjacent 
to GRCs and PGCs were negative for MUC4. MUC4 was negative in the 
tumour cells in all GRC, PGC intestinal type and PGC diffuse type. 
MUCSAC: MUC5AC staining was positive in 10/1 0 normal gastric biopsies. 
The staining was of weak to moderate intensity and expressed in mucous neck 
cells and the surface mucosa (Figure 3.9A). Sections of the gastric mucosa 
adjacent to the tumours in the biopsy and resection specimens of the different 
type of adenocarcinoma all showed the same pattern of staining as the normal 
gastric biopsies. MUC5AC was diffuse and strongly positive in 5/11 (45%) of 
the cytoplasm of tumour cells in intestinal GRC (Figure 3.9B) and 2/6 (33%) 
of diffuse GRC. Two out of ten (20%) of PGC intestinal type showed 
moderate cytoplasmic positivity in 25% of tumour cells. Six (60%) of PGC 
diffuse type showed moderate to strong cytoplasmic staining in 25-75% of 
tumour cells. 
MUCSB: There was no MUC5B staining in the normal gastric biopsies or in 
the gastric mucosa adjacent to the different types of carcinoma. All cases of 
intestinal GRC were negative for MUC5B, while one case of diffuse GRC 
showed mild to weak to moderate positive cytoplasmic staining in the tumour 
cells (Figure 3.10). Only 1/10 (10%) of PGC intestinal type showed mild 
staining, which was luminal and membranous. All cases of PGC primary type 
were negative for MUC5B. 
MUC6: was positive in 50% of the normal gastric biopsies and in the normal 
gastric mucosa adjacent to the different gastric carcinomas. The staining was 
36 
moderate in intensity and distributed in 75% of deep mucus glands (Figure 
3.11). All cases of GRC and PGC diffuse type were negative for MUC6. 
There was weak cytoplasmic positive staining in the tumour cells in 2/10 
(20%) ofPGC of the intestinal type. 
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CHAPTER FOUR 
DISCUSSION 
In this study, three cases (16%) ofGRC showed the presence of moderate number of 
H.pylori in the mucosa away from the tumour. Fewer cases of GRC showed the 
presence of H. pylori compared to 25% of PGC. H.pylori were present on the gastric 
mucosa that did not show intestinal metaplasia (1M), although 1M was present in the 
same specimens. A similar finding was made in a study performed on PGC 
specimens by Dixon et al. (1996). In this study on GRC and PGC, H.pylori were 
never seen in incomplete or complete intestinal metaplasia. This result is consistent 
with the results of Genta et al. (1996), which reported that advanced gastric carcinoma 
and intestinal metaplasia were considered a hostile environment for H. pylori 
organisms and also that H. pylori were seldom seen in the areas of incomplete 
intestinal metaplasia. The finding of H.pylori in this study of GRC was in agreement 
with the results of Elder et al. (1991), who foundH.pylori organisms in cases ofGRC. 
They suggested that the finding of H.pylori in GRC could be explained by chemical 
atrophic gastritis in gastric remnant providing a suitable environment for colonization 
by H.pylori (Elder et al. 1991). However Greene et al. (1996) reported that there was 
no specific association between H.pylori and GRC. Two cases in the present study of 
GRC showed the presence of lymphoid follicles, with no H. pylori present. Genta et 
al. (1993) considered the presence oflymphoid follicles as a feature highly suggestive 
of previous infection by H. pylori organisms. The findings in this study therefore 
suggest previous H. pylori infection with a possible implication of the organism in the 
pathogenesis of GRC. 
Histochemically 80% and 50% of the cases of intestinal type GRC and the diffuse 
type GRC showed the presence of intestinal metaplasia respectively. The metaplasia 
was more prevalent in the cases of intestinal type adenocarcinoma. Furthermore type 
1 1M was seen in 50010 of the intestinal type GRC and 25% of the diffuse type GRC; 
30% of intestinal type GRC had sulphomucin positive incomplete metaplasia (Type 
IIB) while none of the specimens of diffuse GRC showed type IIB 1M. The intestinal 
type GRC showed higher association with type 1 1M and type 1m 1M than diffuse type 
GRC. In comparison with the gastric mucins expressed in the normal gastric biopsies 
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of this study, all nonnal gastric biopsies expressed neutral with no acidic mucin 
found, the findings of which are in keeping with those in other studies (Taylor et al 
1998). In this study intestinal types GRC and PGC showed similar proportions of 
Type I, Type IIA and Type 1m 1M. Also the diffuse types GRC and PGC showed 
similar proportions of Type I, Type lIA and Type 1m 1M, but there was a difference 
in the incidence of 1M between the intestinal and diffuse types of carcinomas. 
Intestinal types GRC and PGC showed more association with sulphomucin positive 
1M (Type 1m). GRC of this study showed higher association with intestinal 
metaplasia in comparison with the published data; 58% of GRC showed association 
with 1M, and 30% showed Type 1m 1M. In other studies, on the other hand, the 
presence of 1M in GRC was reported to be between 22-48% (Domellof et al. 1977, 
Pickford et al. 1984, Schrumpf et al. 1977, Wladimir et al.1985). Although 30% of 
the cases of GRC of this study expressed Type 1m 1M, Wladimir et al. (1985) 
reported the presence of 1M in 22.5% of GRC, of which none expressed Type 1m 
(sulphomucin expressing type). In summary, this study showed that 1M was more 
prevalent in the intestinal type carcinomas of GRC or PGC. These results are similar 
to the other published studies on PGC (Filipe and Potet 1985, Lev 1965, Taylor et al. 
1998). 
More sulphomucin positivity is expected in intestinal than in the diffuse carcinomas, 
as Type 1m 1M is more common in intestinal types GRC and PGC. However in this 
study a similar proportion of diffuse type GRC and intestinal type GRC expressed 
sulphomucin (33% and 27%) respectively, while there was an obvious difference in 
the PGC cases. In fact more of the diffuse PGC (60%) secreted sulphomucin than the 
intestinal type PGC (10%). The findings in this study are also different from those in 
other studies, which showed that sulphomucin tend to predominate in PGC intestinal 
type, and neutral mucins in the PGC diffuse type (Jass and Filipe 1981). Taylor et al. 
(1998), in a study of primary gastric carcinomas, showed that sulphomucin was 
present in 40% of PGC intestinal type and in 14% PGC diffuse type. Whilst our 
findings could imply differences due to different genetic backgrounds, ethnicity, or 
even technical problems, it must be remembered that Taylor et al. (1998) perfonned 
their studies in the same setting. It is obvious that the question of the incidence of 
sulphomucin expression in gastric carcinoma of the intestinal and diffuse types needs 
further investigation. 
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Immunohistochemically nonnal gastric mucosa expressed MUCl, MUC4, MUC5AC 
and MUC6. There was a strong positive MUCl, and MUCIC, weak positive MUC4 
and strong positive MUC5AC in 100% of the biopsies and moderately positive MUC6 
in 60% of the cases. Taylor et aI. (1998) showed positive MUC4, MUC5 and MUC6. 
Ho et al. (1995) have shown that nonnal stomach mucosa was characterized by the 
expression of MUCl, MUC5 and MUC6, while MUC2, MUC3 and MUC4 were 
negative. In this study, MUCI and MUCIC were present in the parietal cells of the 
gastric fundic glands in 100% of the cases and it was cytoplasmic and membranous, 
while the surface mucus neck cells and antrum type glands were always negative. 
The results were in agreement with Ho et a1. (1995) who showed that MUCI was 
expressed in 100% of the nonnaI gastric mucosa. In comparison, Taylor et aI. (1998) 
showed that 20% of the cases of nonnal gastric tissue were reactive to MUCI 
antibodies and it was the parietal, surface mucosa and mucus neck cells that were 
positive. In this study MUC4 was positive in basal mucus glands in 100% ofnonnal 
gastric biopsies. The results in this study were similar to a previous study done in the 
same department by Taylor et al (1998). MUC4 is also expressed in respiratory and 
reproductive tracts and gastric mucosa and to a lesser extent by goblet cells of the 
colorectum (Winterford et al. 1999, Seregni et a1. 1997). However other studies 
showed that gastric mucosa did not express MUC4 (Ho et aI. 1995). Ho has repeated 
MUC4 staining on nonnal gastric mucosa using the same antibody that was used in 
this study, and has confinned the presence of MUC4 (personal communication), in 
gastric tissue. MUC5AC was present in the surface and mucus neck cells of all 
nonnal gastric mucosa (control) as well as in surface and mucus neck cells in the 
gastric mucosa adjacent to the various gastric carcinomas. These findings are similar 
to other studies (Lopez-Ferrer et a1. 2000, Machado et a1. 2000). MUC5AC is a 
secretory gel fonning mucin, nonnally expressed in the superficial and foveolar 
epithelium of gastric mucosa and neck cells, while its expression is absent in the deep 
glands of the gastric body and pyloric glands of the antrum (Machado et a1. 2000). 
The expression of MUC6 by the nonnaI gastric mucosa was similar to the findings in 
other studies (Ho et aI. 1995, Machado et aI. 2000). MUC2 and MUC5B were 
negative in the gastric epithelium. 
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The results of staining with antibody to MUC3 have not been included because of 
technical problem with the antibody, which gave a false positive reaction with nonnal 
gastric mucosa. Please see appendices 3.1 and 3.2. 
Intestinal GRC showed strong expression of MUCI in 36%, MUC2 inl8% and 
MUC5AC in 45% of tumours, while diffuse type GRC showed strong expression of 
MUCI inI7%, MUC2 in 17%, MUC5AC in 33% and MUC5B in 17% of tumours. In 
contrast PGC intestinal type showed strong expression of MUCI in 70%, MUC2 in 
40%, MUC5AC in 20% and MUC6 in 20% of tumour cells, while PGC diffuse type 
showed strong expression ofMUCI in 30%, MUC2 in 40% and MUC5AC in 60% of 
tumour cells. The expression of MUC2 was aberrant in the intestinal type GRC, 
while MUC4 and MUC6 were completely absent in contrast to the nonnal stomach. 
On the other hand diffuse type GRC showed aberrant expression of MUC2 and 
MUC5B in comparison to the nonnal gastric mucosa. Fewer intestinal type GRC 
cases expressed MUC 1 and MUC2 than PGC. Other than that there were no major 
differences between the mucin profiles of GRC and PGC diffuse type. There were no 
published results on the immunohistochemical mucin profile concerning GRC to 
compare with our results. The results in the GRC and PGC resembled, to some extent 
the published results on PGC, although some differences were also present. Taylor et 
al. (1998) found considerable difference between PGC diffuse type and PGC 
intestinal type. The expression ofMUC1, MUC5 and MUC6 were strong in late stage 
PGC intestinal type, while MUC2, MUC5, MUC6 and MUC7 were present in various 
combinations in a large proportion of PGC diffuse type. More cases of intestinal 
types GRC and PGC in this study expressed MUC 1 than the diffuses types GRC and 
PGC, the results of which were in agreement with the findings of Taylor et al. (1998) 
and Ho et al. (1995), who showed that there was an increased expression of mucin 
gene in intestinal type PGC as compared to the diffuse type. The aberrant expression 
of MUC2 in the GRC and PGC cases in this study was consistent with the results in 
the literature, which showed that MUC2 was up regulated in PGC (Comberg et al. 
1999, Lopez-Ferrer et al. 2000). In this study 33% of diffuse GRC and 45% of 
intestinal GRC were positive to MUC5AC, while 60% of PGC diffuse type and 20% 
ofPGC intestinal type expressed MUC5AC in comparison to 100% in nonnal gastric 
mucosa. Ho et a!. (1995) showed that the expression ofMUC5 levels was decreased 
in gastric cancer in comparison to the nonnal gastric mucosa. Reis et al. (1997) found 
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that PGC diffuse type expressed higher MUC5AC than PGC intestinal type, the 
finding of which were in agreement with the results of PGC of this study, but not to 
those of ORC. In a study performed by Wang et al. (2003) they found that patients 
with MUCI positivelMUC5AC negative gastric carcinoma showed a low survival rate 
in comparing with MUCInegativelMUC5AC positive gastric carcinoma patients. 
No attempt was made to compare the findings in the study with survival because 
insufficient follow-up information was available. 
It would be of interest to group the ORCs by their location in the stomach to 
determine whether there are morphological, histochemical and immunohistochemical 
differences in tumour arising near the site of gastro-jejunal anastomosis compared to 
those arising in the cardiac and fundic regions. A larger number of cases and more 
clinical information, including long-term follow-up, will be required. Such a study 
would permit the mucin in the ORCs be correlated, not only with the location of the 
tumour in the gastric remnant, but also with survival. 
Information about the prevalence of PGC in the general population, in South Africa 
and other parts of the world, versus the prevalence of ORC is needed to determine 
whether partial gastrectomy for benign disease is indeed a risk factor for ORC. 
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CONCLUSION 
In general morphologically, histochemically and immunohistochemically gastric 
remnant carcinoma closely resembles primary gastric carcinoma, this includes the 
finding of a high association of Type I and lIB intestinal metaplasia in the intestinal 
types of both GRC and PGC compared to the diffuse types of GRC and PGC, 
although a smaller percentage ofGRCs expressed MUCI and MUC2 than PGCs. 
The similarity of the histochemical and immunohistochemical mucin profile of GRC 
compared to PGC suggests that they may not be distinct pathological entities. 
Future studies are needed to answer some of the unexplained findings such as the 
more frequent expression of sulphated mucin in diffuse types GRC and PGC 
compared to intestinal type GRC and PGC, a finding which is different to that of 
published series. 
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APPENDIX 
Appendix I: TNM staging of gastric carcinoma 
Primary tumor 
TX Primary tumour can not be assessed 
TO No evidence of primary tumour 
Tis Carcinoma insitu: Intraepithelial tumour without invasion of the lamina propria 
TI Invasion oflamina propria (Tla) or submucosa (Tlb) 
T2 Invasion of muscularis propria (T2a) or subserosa (T2b) 
T3 Tumour penetrates serosa 
T4 Invasion of adjacent structures 
Regionallympb node metastsis 
NX Regional lymph nodes cannot be assessed 
NO No regional lymph node metastasis 
NI Metastasis in 1 - 6 perigastric lymph nodes 
N2 Metastasis in 7 - 15 perigastric lymph nodes 
N3 Metastasis in more than 15 perigastric lymph nodes 
Distant metastasis 
MO No distant metastasis 
Ml Distant metastasis 
49 
Staging of gastric carcinoma by the TNM method 
0 Tis NO MO 
IA Tl NO MO 
IB Tl Nl MO 
T2 NO MO 
II Tl N2 MO 
T2 Nl MO 
T3 NO MO 
IlIA T2 N2 MO 
T3 Nl MO 
T4 NO MO 
11m T3 N2 MO 
N T4 Nl,2,3 MO 
TI-4 N3 MO 
AnyT AnyN Ml 
Appendix 2: Supplier of antibodies used in the immunohistochemical study. 
Biotinylated rabbit-anti-mouse antibody- Dako, Copenhagen, Denmark. 
Biotinylated swine-anti-rabbit antibody- Dako, Copenhagen, Denmark. 
Biotinylated rabbit-anti-chicken antibody- Biogenesis, Poole, UK. 
Strep-avidin HRP- Dako, Copenhagen, Denmark. 
Appendix 3.1: 
MUC3 is a membrane bound mucin, expressed in small intestine and colorectum. It is 
secreted by columnar and goblet cells of 1M and colorectum (Jass 2000). In this 
study, all normal gastric biopsies and the gastric mucosa adjacent to the various 
gastric carcinoma expressed MUC3 in the cytoplasm of mucus secreting cells of the 
deep glands as well as in the goblet cells of intestinal metaplasia. Taylor et al. (1998) 
and Ho et al. (1995) did not find MUC3 in the normal gastric mucosa. 
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The MUC3 antibody used in the first instance was a polyc1onal rabbit anti-MUC3 
antibody (Biomeda, lot no 8769, cat. no V2056, expiry date 4/04). Upon repeating 
the staining procedure with another MUC3 antibody from the same company with the 
same specifications, non-specific and background staining was seen in the tissue. 
However MUC3 was positive in the goblet cells, which is in agreement with the 
findings in other studies (Jass 2000, Ho et al. 1995). In this study 40% of intestinal 
type PGC expressed MUC3 in less than 25% of the tumour cells, while none of GRC 
or diffuse type PGC expressed MUC3. These results were in contrast to that of 
Taylor et al. (1998), which showed no expression ofMUC3 in the advanced intestinal 
PGC and positive staining in 29% of the diffuse type PGC. The apparent positive 
staining for MUC3 in normal gastric mucosa was contrary to published results (Taylor 
et a. 1998, Ho et al. 1995); similarly the results in PGCs are different from those of 
Taylor et al. (1998) in a study performed in the same department. 
Given the uncertainity about MUC 3 staining in the normal control slides, the 
immunohistochemical results in the PGCs that conflicted with those of published 
studies as well as the manufacturer agreeing that there was a problem with the 
antibody, a decision was made to omit the results ofMUC3 for this study. 
Appendix 3.2: Letter from the company for MU 
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